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ABSTRACT
Metformin is typically the first pharmacologic
treatment recommended for type 2 diabetes
mellitus (T2DM), but many patients do not
achieve glycemic control with metformin alone
and eventually require combination therapy
with other agents. Canagliflozin, a sodium
glucose co-transporter 2 (SGLT2) inhibitor, was
assessed in a comprehensive Phase 3 clinical
development program consisting of*10,000
participants, of which*80% were on
background therapy that consisted of
metformin alone or in combination with other
antihyperglycemic agents (AHAs; e.g.,
pioglitazone, sulfonylurea, and insulin). In
addition, the efficacy and safety of
canagliflozin and metformin as the initial
combination therapy and canagliflozin
monotherapy were assessed versus metformin
in treatment-naı¨ve patients with T2DM. Across
studies in patients with T2DM who were on
metformin alone or in combination with other
AHAs, canagliflozin 100 and 300 mg provided
improvements in glycated hemoglobin for up to
104 weeks. Canagliflozin was also associated
with reductions in body weight and systolic
blood pressure when added to background
therapy consisting of metformin alone or with
other AHAs. Canagliflozin was generally well
tolerated, with increased incidence of adverse
events (AEs) related to the mechanism of SGLT2
inhibition (i.e., genital mycotic infections,
urinary tract infections, and osmotic
diuresis-related AEs). Consistent with its
insulin-independent mechanism of action,
canagliflozin was associated with low rates of
hypoglycemia when background therapy did
not include sulfonylurea or insulin. Due to its
favorable efficacy and safety profile, these
results suggest that adding canagliflozin to a
background regimen consisting of metformin or
implementing treatment with a fixed-dose
regimen of canagliflozin and metformin would
provide an effective and safe treatment regimen
for T2DM management.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is
characterized by chronic hyperglycemia and is
closely associated with comorbidities, including
obesity, hypertension, and dyslipidemia, and an
increased risk of cardiovascular disease and
mortality [1–4]. The interplay of these factors
can complicate T2DM management; therefore,
therapeutics that control weight and blood
pressure (BP) in addition to blood glucose
would be beneficial [2].
The first pharmacologic intervention
typically recommended for the treatment of
T2DM is metformin [5–7], which works
primarily by decreasing hepatic glucose
production [5, 8]. Metformin may also reduce
endogenous glucose production by delaying
intestinal glucose absorption [8], and recent
evidence suggests that metformin’s action in
the gut is responsible for its glucose-lowering
effect [9]. Metformin has a well-established
efficacy and safety profile, is not associated with
hypoglycemia or weight gain, may reduce the
risk of myocardial infarction and death, and is
inexpensive [5, 6, 10]. Despite these advantages,
many patients are unable to control their blood
glucose levels with metformin alone and require
combination therapy with other
antihyperglycemic agents (AHAs) [5, 11, 12].
Some of the AHAs frequently used for
combination therapy have undesirable effects,
such as weight gain, hypoglycemia, and
decreased efficacy over time [5, 11, 12].
Sodium glucose co-transporter 2 (SGLT2)
inhibitors lower the renal threshold for
glucose (RTG) in patients with T2DM, thus
increasing urinary glucose excretion and
leading to mild osmotic diuresis and a net
caloric loss [5, 13]. This mechanism is
independent of insulin and complementary to
those of other classes of AHAs, including
metformin [5, 13]. In addition to improving
glycemic control, SGLT2 inhibitors have been
associated with modest weight loss and BP
reductions in patients with T2DM [14]. SGLT2
inhibitors are additionally associated with
improvements in measures of beta-cell
function, including glucose sensitivity and
insulin secretion [15–17]. Along with
potentially having favorable effects on
components of T2DM, the benefits of this
class may also improve cardiovascular
outcomes in patients with T2DM [18, 19]. Due
to their favorable efficacy and tolerability
profile, the American Diabetes Association
recommends adding an SGLT2 inhibitor in
patients whose T2DM is inadequately
controlled with metformin [6], and the
American Association of Clinical
Endocrinologists Glycemic Control Algorithm
identifies SGLT2 inhibitors as the first choice of
oral medications for add-on therapy in patients
inadequately controlled on metformin [7].
Canagliflozin, an SGLT2 inhibitor, is
approved in many countries for the treatment
of adults with T2DM [20], and a fixed-dose
combination of canagliflozin and metformin, is
also available for the treatment of adults with
T2DM [21]. When administered as an add-on
treatment to metformin, canagliflozin was
associated with reductions in glycated
hemoglobin (HbA1c), weight loss, and BP
lowering in a broad range of patients in
Phase 2 [22, 23] and Phase 3 studies [24–26].
These effects were also observed in a Phase 3
study of the initial combination therapy with
canagliflozin plus metformin [27]. The benefits
noted in these studies were similar to those seen
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in other Phase 3 studies when canagliflozin was
administered to patients on a background of
metformin plus pioglitazone [28], metformin
plus sulfonylurea [29, 30], or metformin plus
insulin [31]. This review summarizes the
efficacy and safety of canagliflozin when used
in combination with metformin in Phase 3
studies in patients with T2DM.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
Overview of Clinical Studies
of Canagliflozin in Combination
with Metformin
Table 1 provides an overview of the designs and
patient populations of the Phase 3 studies, in
which canagliflozin was administered with
metformin alone or in combination with
another AHA (i.e., pioglitazone, sulfonylurea,
and insulin) in patients with T2DM. Key
efficacy analyses in these studies included
changes from baseline in HbA1c, body weight,
and systolic BP. Safety was assessed based on
adverse event (AE) reports.
Two randomized, double-blind, Phase 3
studies evaluated the efficacy and safety of
canagliflozin 100 and 300 mg as add-on to
metformin [24–26]. A 52-week study in
1284 participants evaluated the efficacy and
safety of canagliflozin versus placebo at week 26
and versus sitagliptin 100 mg at week 52
(ClinicalTrials.gov Identifier, NCT01106677)
[24]. Safety analyses included participants who
receivedcanagliflozin100or300 mgor sitagliptin
100 mg over 52 weeks and those who switched
from placebo to sitagliptin after 26 weeks
(placebo/sitagliptin group). The second study
(NCT00968812) evaluated canagliflozin 100 and
300 mg versus glimepiride in 1450 participants at
52 weeks [25] and 104 weeks [26]. A separate
randomized, double-blind, Phase 3 study
evaluated the efficacy and safety of the initial
combination therapy with canagliflozin 100 or
300 mg plus metformin versus metformin alone
in 1186 drug-naı¨ve patients over 26 weeks
(NCT01809327) [27]. This study also evaluated
the efficacy and safety of canagliflozin 100 and
300 mgmonotherapy versus metformin [27].
A randomized, double-blind, Phase 3 study
evaluated canagliflozin 100 and 300 mg as
add-on to metformin plus pioglitazone in
342 patients over 52 weeks (NCT01106690)
[28]. Patients assigned to placebo were
switched to sitagliptin 100 mg after 26 weeks.
Efficacy comparisons were made versus placebo
at week 26 and versus sitagliptin 100 mg at
week 52. Safety data at week 52 included
patients in the placebo group who were
switched to sitagliptin at week 26.
Two randomized, double-blind, Phase 3
studies evaluated the efficacy and safety of
canagliflozin as add-on to metformin plus
sulfonylurea. A placebo-controlled study in
469 patients evaluated the efficacy and safety
of canagliflozin 100 and 300 mg as add-on to
metformin plus sulfonylurea over 52 weeks
(NCT01106625) [29]. A separate head-to-head
study evaluated the efficacy and safety of
canagliflozin 300 mg versus sitagliptin 100 mg
as add-on to metformin plus sulfonylurea over
52 weeks (NCT01137812) [30].
An 18-week, randomized, double-blind,
placebo-controlled study of canagliflozin 100
and 300 mg as add-on therapy to metformin or
metformin plus sulfonylurea was conducted in
Asian patients with T2DM in China, Malaysia,
and Vietnam (NCT01381900) [32].
Of 676 participants, 330 were receiving
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Table 1 Study design and patient populations of Phase 3 studies of canagliﬂozin in combination with metformin in
patients with T2DM
Study Study design Patients Key inclusion criteria
Add-on to MET vs
PBO/SITA [24]
PBO-controlled, 26-week core
period; active-controlled (vs
SITA), 26-week extension period
N = 1284;
PBO/SITA,
n = 183;
SITA 100 mg,
n = 366;
CANA 100 mg,
n = 368;
CANA 300 mg,
n = 367
C18 and B80 years old;
HbA1c C7.0% and B10.5%;
Receiving stable MET dose
(C2000 mg/day [or C1500 mg/day if
unable to tolerate a higher dose]) for
C8 weeks;
eGFR C55 mL/min/1.73 m2a
Add-on to MET vs
GLIM [25, 26]
Active-controlled (vs GLIM)
52-week core period and 52-week
extension
N = 1450;
GLIM, n = 482;
CANA 100 mg,
n = 483;
CANA 300 mg,
n = 485
C18 and B80 years old;
HbA1c C7.0% and B9.5%;
Receiving stable MET dose
(C2000 mg/day [or C1500 mg/day if
unable to tolerate a higher dose]) for
C10 weeks;
eGFR C55 mL/min/1.73 m2a
Initial
combination
with
CANA ?MET
[27]
Initial combination therapy with
CANA ?MET vs each
component for 26 weeks
N = 1186;
CANA 100 mg/
MET, n = 237;
CANA 300 mg/
MET, n = 237;
CANA 100 mg,
n = 237;
CANA 300 mg,
n = 238;
MET, n = 237
C18 and\75 years old;
HbA1c C7.5% and B12.0%;
AHA-naı¨ve (not on AHA therapy or off
for C12 weeks before screening);
eGFR C60 mL/min/1.73 m2
Add-on to
MET ? PIO vs
PBO/SITA [28]
PBO-controlled, 26-week core
period; active-controlled (vs
SITA), 26-week extension period
N = 342;
PBO/SITA,
n = 115;
CANA 100 mg,
n = 113;
CANA 300 mg,
n = 114
C18 and B80 years old;
HbA1c C7.0% and B10.5%;
Receiving stable MET dose
(C2000 mg/day [or C1500 mg/day if
unable to tolerate a higher dose]) and
PIO 30 or 45 mg/day for C8 weeks;
eGFR C55 mL/min/1.73 m2a
662 Diabetes Ther (2016) 7:659–678
Table 1 continued
Study Study design Patients Key inclusion criteria
Add-on to
MET ? SU vs
PBO [29]
PBO-controlled, 26-week core
period; PBO-controlled, 26-week
extension period
N = 469;
PBO, n = 156;
CANA 100 mg,
n = 157;
CANA 300 mg,
n = 156
C18 and B80 years old;
HbA1c C7.0% and B10.5%;
Receiving stable MET dose
(C2000 mg/day [or C1500 mg/day if
unable to tolerate a higher dose]) and
SU (at least half of maximally labeled
dose) for C8 weeks;
eGFR C55 mL/min/1.73 m2a
Add-on to
MET ? SU vs
SITA [30]
Active-controlled, 52-week
treatment period
N = 756;
CANA 300 mg,
n = 377;
SITA 100 mg,
n = 378
C18 years old;
HbA1c C7.0% and B10.5%;
Receiving stable MET dose
(C2000 mg/day [or C1500 mg/day if
unable to tolerate a higher dose]) and
SU (at least half of maximally labeled
dose) for C8 weeks;
eGFR C55 mL/min/1.73 m2a
Asian population:
add-on to
MET ± SU vs
PBO [32]
PBO-controlled, 18-week treatment
period
N = 676;
PBO, n = 226;
CANA 100 mg,
n = 223;
CANA 300 mg,
n = 227
C18 and B80 years old;
HbA1c C7.0% and B10.5%;
Receiving stable MET dose
(C1500 mg/day) with or without SU
(at least half of maximally labeled dose)
for C8 weeks;
eGFR C60 mL/min/1.73 m2
Add-on to
MET ? insulin
vs PBO [31]
Prespeciﬁed 18-week substudy in a
subset of patients from the
ongoing PBO-controlled,
CANVAS trial
N = 432;
PBO, n = 145;
CANA 100 mg,
n = 139;
CANA 300 mg,
n = 148
C30 years old with documented,
symptomatic, atherosclerotic
cardiovascular disease, or C50 years old
with C2 CV risk factors at screening;
Receiving stable MET dose
(C2000 mg/day) and insulin
C30 IU/day (basal and/or bolus);
HbA1c C7.0% and B10.5%;
eGFR C30 mL/min/1.73 m2
AHA antihyperglycemic agent, CANA canagliﬂozin, CANVAS CANagliﬂozin cardioVascular Assessment Study,
CV cardiovascular, eGFR estimated glomerular ﬁltration rate, GLIM glimepiride, MET metformin, PBO placebo,
PIO pioglitazone, SITA sitagliptin, SU sulfonylurea, T2DM type 2 diabetes mellitus
a The required eGFR was C60 mL/min/1.73 m2 if based on restriction of metformin use in the local label
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metformin monotherapy (metformin stratum)
and 346 were receiving metformin plus
sulfonylurea (metformin plus sulfonylurea
stratum) at baseline.
An 18-week, prespecified substudy of the
ongoing CANagliflozin cardioVascular
Assessment Study (CANVAS; NCT01032629)
evaluated the efficacy and safety of
canagliflozin 100 and 300 mg compared with
placebo in 432 patients with T2DM and a
history or high risk of cardiovascular disease
whose background therapy consisted of
metformin plus insulin C30 IU/day (basal and/
or bolus) [31].
Glycemic Efficacy
Combination with Metformin Alone
Figure 1 presents the least squares (LS) mean
changes in HbA1c in the core periods of Phase
3 studies of canagliflozin added to metformin
alone or in combination with other AHAs and
in the initial combination therapy study. In
the study of canagliflozin versus placebo/
sitagliptin, canagliflozin 100 and 300 mg
significantly lowered HbA1c versus placebo at
week 26 (p\0.001) [24]. At week 52,
canagliflozin 100 mg demonstrated
noninferiority and canagliflozin 300 mg
demonstrated superiority in lowering HbA1c
versus sitagliptin [24].
At week 52, canagliflozin 100 mg
demonstrated noninferiority and canagliflozin
300 mg demonstrated superiority in lowering
HbA1c in the head-to-head study versus
glimepiride [25]. At week 104, HbA1c
reductions were -0.65%, -0.74%, and -0.55%
with canagliflozin 100 and 300 mg and
glimepiride, respectively [26].
In the metformin stratum of the study in
Asian patients, HbA1c reductions from baseline
at week 18 were significantly larger with
canagliflozin 100 and 300 mg compared with
placebo (p\0.001) [32].
In the initial combination therapy study,
canagliflozin 100 mg/metformin and
canagliflozin 300 mg/metformin significantly
lowered HbA1c versus metformin
monotherapy at week 26 (p = 0.001) [27].
Combination with Metformin Plus Other
AHAs
In the placebo-controlled add-on to metformin
plus pioglitazone study, significant reductions
in HbA1c were seen with canagliflozin 100 and
300 mg versus placebo at week 26 (p\0.001)
[28]. At week 52, reductions in HbA1c with
canagliflozin 100 and 300 mg were -0.92% and
-1.03%, respectively.
In the placebo-controlled add-on to
metformin plus sulfonylurea study,
canagliflozin 100 and 300 mg significantly
lowered HbA1c versus placebo over 26 weeks
(p\0.001) [29]. Reductions in HbA1c with
canagliflozin 100 and 300 mg versus placebo
were sustained over 52 weeks (-0.74%, -0.96%,
and 0.01%, respectively). In the head-to-head
study of canagliflozin as add-on to metformin
plus sulfonylurea, canagliflozin 300 mg
demonstrated superiority in HbA1c lowering
versus sitagliptin 100 mg over 52 weeks [30].
Among patients in the metformin plus
sulfonylurea stratum of the study in Asian
patients, reductions in HbA1c were
significantly larger with canagliflozin 100 and
300 mg compared with placebo at week 18
(p\0.001) [32].
In the subset of CANVAS patients whose
background therapy consisted of metformin
plus insulin, canagliflozin 100 and 300 mg
significantly lowered HbA1c compared with
placebo over 18 weeks (p\0.001) [31].
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Fig. 1 Changes from baseline in HbA1c in Phase 3 studies
of canagliﬂozin in combination with metformin ± other
AHAs [24–32]. a p\0.001 versus PBO; b p = 0.001
versus MET; c p = 0.001 versus CANA 100 mg; d
p = 0.001 versus CANA 300 mg; e Noninferiority
p = 0.001 versus MET. AHA antihyperglycemic agent,
CANA canagliﬂozin, GLIM glimepiride, HbA1c glycated
hemoglobin, LS least squares, MET metformin,
PBO placebo, PIO pioglitazone, SE standard error,
SITA sitagliptin, SU sulfonylurea
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Body Weight Reductions
Combination with Metformin Alone
Figure 2 depicts LS mean percent changes in
body weight in the core periods of Phase 3
studies of canagliflozin in combination with
metformin. In the study versus placebo/
sitagliptin, canagliflozin provided significant
body weight reductions at week 26 compared
with placebo (p\0.001) [24]; reductions were
sustained at week 52 (p\0.001) [24].
In the active-controlled study versus
glimepiride, significant body weight reductions
were seen with canagliflozin 100 and 300 mg
compared with an increase with glimepiride at
week 52 (p\0.0001) [25]. Body weight
reductions with canagliflozin 100 and 300 mg
versus glimepiride were sustained at week 104;
changes from baseline were -4.1%, -4.2%, and
0.9% (-3.6, -3.6, and 0.8 kg), respectively [26].
In the metformin stratum of the study in
Asian patients, greater reductions in body
weight were seen with canagliflozin 100 and
300 mg compared with placebo at week 18
(p\0.001) [32].
At week 26 in the initial combination
therapy study, significantly greater weight loss
was seen with canagliflozin 100 mg/metformin
and canagliflozin 300 mg/metformin than with
metformin alone (p = 0.001) [27].
Combination with Metformin Plus Other
AHAs
Significant reductions in body weight were seen
with canagliflozin 100 and 300 mg versus
placebo as add-on to metformin plus
pioglitazone at week 26 (p\0.001) [28]. At
week 52, body weight reductions with
canagliflozin 100 and 300 mg were sustained
(-2.7% and -3.7% [-2.5 and -3.6 kg],
respectively).
In the placebo-controlled add-on to
metformin plus sulfonylurea study,
canagliflozin 100 and 300 mg significantly
lowered body weight versus placebo over
26 weeks (p\0.001) [29]. At week 52,
reductions in body weight were -2.2%,
-3.2%, -0.9% (-2.0, -3.1, and -1.0 kg) with
canagliflozin 100 and 300 mg and placebo,
respectively. In the head-to-head study of
canagliflozin as add-on to metformin plus
sulfonylurea, canagliflozin 300 mg significantly
lowered body weight versus sitagliptin 100 mg
over 52 weeks (p\0.001) [30]. Among Asian
patients in the metformin plus sulfonylurea
stratum, significant reductions in body weight
were seen with canagliflozin 100 and 300 mg
compared with placebo at week 18 (p\0.001)
[32].
In the subset of CANVAS patients on
metformin plus insulin, canagliflozin 100 and
300 mg significantly lowered body weight
compared with placebo over 18 weeks
(p\0.001) [31].
Changes in Systolic BP
Combination with Metformin Alone
Figure 3 depicts LS mean changes in systolic BP
in the core periods of Phase 3 studies of
canagliflozin in combination with metformin.
In the study of canagliflozin versus placebo/
sitagliptin, significant reductions in systolic BP
were seen with canagliflozin 100 and 300 mg
versus placebo at week 26 (p\0.001) [24].
Significant systolic BP reductions were also
seen at week 52 with canagliflozin 100 and
300 mg compared with sitagliptin 100 mg
(p\0.001).
In the study of canagliflozin versus
glimepiride, canagliflozin 100 and 300 mg
were associated with reductions in systolic BP
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Fig. 2 Changes from baseline in body weight in Phase 3
studies of canagliﬂozin in combination with met-
formin ± other AHAs [24–32]. a Absolute changes from
baseline in kg are shown in parentheses; b p\0.001 versus
PBO; c p\0.001 versus SITA 100 mg; d p\0.0001 versus
GLIM; e p = 0.001 versus MET; f p = 0.016 versus MET;
g p = 0.002 versus MET. AHA antihyperglycemic agent,
CANA canagliﬂozin, GLIM glimepiride, LS least squares,
MET metformin, PBO placebo, PIO pioglitazone,
SE standard error, SITA sitagliptin, SU sulfonylurea
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Fig. 3 Changes from baseline in systolic BP in Phase 3
studies of canagliﬂozin in combination with met-
formin ± other AHAs [24–32]. a p\0.001 versus PBO;
b p\0.001 versus SITA 100 mg; c p = NS versus MET; d
p\0.01 versus PBO; e p\0.025 versus PBO.
AHA antihyperglycemic agent, BP blood pressure,
CANA canagliﬂozin, GLIM glimepiride, LS least squares,
MET metformin, NS not signiﬁcant, PBO placebo,
PIO pioglitazone, SE standard error, SITA sitagliptin,
SU sulfonylurea
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versus glimepiride at week 52 [25] and week 104
(-2.0, -3.1, and 1.7 mmHg, respectively) [26].
In Asian patients, reductions in systolic BP
were numerically greater with canagliflozin 100
and 300 mg compared with placebo in the
metformin stratum at week 18 [32].
At week 26 in the initial combination
therapy study, canagliflozin 100 mg/
metformin and canagliflozin 300 mg/
metformin were associated with numerically
larger reductions in systolic BP compared with
metformin monotherapy [27].
Combination with Metformin Plus Other
AHAs
Significant reductions in systolic BP were seen
with canagliflozin 100 and 300 mg versus
placebo as add-on to metformin plus
pioglitazone at week 26 (p\0.01 and
p\0.025, respectively) [28]. At week 52,
reductions in systolic BP were -3.4 and
-3.7 mmHg with canagliflozin 100 and
300 mg, respectively.
In the placebo-controlled add-on to
metformin plus sulfonylurea study,
canagliflozin 100 and 300 mg provided
numerical reductions in systolic BP versus
placebo over 26 weeks [29]. At week 52,
changes in systolic BP were -3.7, -2.9, and
0.1 mmHg with canagliflozin 100 and 300 mg
and placebo, respectively. In the head-to-head
study of canagliflozin as add-on to metformin
plus sulfonylurea, canagliflozin 300 mg
significantly lowered systolic BP versus
sitagliptin 100 mg over 52 weeks (p\0.001)
[30]. In the metformin plus sulfonylurea
stratum of the study in Asian patients, larger
changes in systolic BP were seen with
canagliflozin 100 and 300 mg compared with
placebo at week 18 [32].
In the subset of CANVAS patients on
metformin plus insulin, reductions in systolic
BP were seen with canagliflozin 100 and 300 mg
compared with placebo at week 18 (p\0.001
for canagliflozin 300 mg versus placebo) [31].
Efficacy of Canagliflozin Monotherapy
Versus Metformin
The initial combination study also evaluated
the efficacy and safety of canagliflozin 100 and
300 mg monotherapy versus metformin in
treatment-naı¨ve patients with T2DM [27].
Canagliflozin 100 and 300 mg demonstrated
noninferiority in lowering HbA1c versus
metformin at week 26 (noninferiority
p = 0.001; Fig. 1). Body weight reductions were
significantly greater with canagliflozin 100 and
300 mg versus metformin (p = 0.016 and
p = 0.002, respectively; Fig. 2). Reductions in
systolic BP were also observed with canagliflozin
100 and 300 mg compared with metformin
(Fig. 3).
Safety of Canagliflozin in Combination
with Metformin
Overall Safety and Selected AEs
Canagliflozin was generally well tolerated, with
similar safety and tolerability profiles seen
across studies in combination with metformin
[24–32]. Table 2 summarizes safety data in
Phase 3 studies of canagliflozin in
combination with metformin alone, and
Table 3 summarizes safety data in the studies
of canagliflozin in combination with metformin
and other AHAs. In addition to providing the
overall incidence of AEs, the tables show the
incidence of selected AEs related to SGLT2
inhibition, including urinary tract infections,
genital mycotic infections, osmotic
diuresis-related AEs, and volume
depletion-related AEs. Overall, the frequency
of AEs leading to discontinuation and serious
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AEs was generally low with canagliflozin versus
comparators [24–32]. The incidence of genital
mycotic infections and osmotic diuresis-related
AEs was generally higher with canagliflozin
versus comparators. Rates of volume
depletion-related AEs, including postural
dizziness and orthostatic hypotension, were
low across groups in each study.
Gastrointestinal-related AEs, such as
diarrhea, nausea, and vomiting, which are
commonly associated with metformin, were
generally similar across groups in each study
[24–32]. At week 26 in the initial combination
therapy study, the incidence of
gastrointestinal-related AEs was 4.6%, 4.6%,
and 4.2% with canagliflozin 100 mg/
metformin, canagliflozin 300 mg/metformin,
and metformin, respectively; rates were 1.7%
with canagliflozin 100 mg and 2.9% with
canagliflozin 300 mg [27].
Diabetic ketoacidosis was rare in the
canagliflozin clinical development program
[33]. No serious AEs of diabetic ketoacidosis
were seen with canagliflozin when it was added
to background therapy consisting of metformin
alone or in combination with pioglitazone [33].
There was one serious AE of ketoacidosis with
canagliflozin 300 mg in the initial combination
therapy study [33]. This event occurred in a
62-year-old man on the 18th day of treatment.
Confounding factors were: an abscessed boil of
the anterior abdominal wall that required
dissection and antibiotics; chronic pancreatitis,
which was detected by abdominal ultrasound;
and heart failure class II and treatment with
indapamide. There was one serious AE of
ketoacidosis with canagliflozin 100 mg in the
placebo-controlled add-on to metformin plus
sulfonylurea study [33]. The event occurred in a
47-year-old woman who had nearly 50-kg
weight loss over 2 years and was subsequently
diagnosed with type 1 diabetes. There were no
serious AEs of diabetic ketoacidosis in the subset
of patients from the CANVAS trial who were on
metformin plus insulin during the 18-week
treatment period.
An interim safety analysis of the overall
CANVAS study identified an increased risk for
lower limb amputation with canagliflozin (7.3,
5.4, and 3.0 per 1000 patient-years with
canagliflozin 100 and 300 mg and placebo,
respectively) [34]. This safety signal was not
observed in a pooled analysis of 12 completed
Phase 3 and Phase 4 studies representing a
broad patient population on background
metformin or other AHAs (data on file), or in
an analysis of the CANVAS-R (renal outcomes;
NCT01989754) study. In pooled Phase 3 studies,
an increased risk for fracture, primarily in the
upper and lower extremities, was observed with
canagliflozin, which was driven by a higher
incidence in patients from the CANVAS study
[35]. Additional data regarding the risk for
amputation and fracture with canagliflozin
will be available upon completion of the
CANVAS and CANVAS-R studies in 2017.
Hypoglycemia
As an SGLT2 inhibitor, canagliflozin reduces
reabsorption of filtered glucose and lowers RTG,
thereby increasing urinary glucose excretion
and lowering elevated plasma glucose
concentrations in patients with T2DM
[20, 36]. The risk of hypoglycemia with
canagliflozin is expected to be low because
RTG typically remains above the threshold for
hypoglycemia (*3.9 mmol/L) in patients with
T2DM, and very little urinary glucose excretion
occurs when plasma glucose levels are below
RTG [20].
In Phase 3 studies of canagliflozin,
documented hypoglycemia episodes were
defined as biochemically documented episodes
(concurrent fingerstick glucose or plasma
674 Diabetes Ther (2016) 7:659–678
glucose B3.9 mmol/L with or without
symptoms) and severe episodes (requiring the
assistance of another individual or resulting in
seizure or loss of consciousness) [24–32]. In
general, patients who were not on background
therapy that included sulfonylurea had a low
incidence of hypoglycemia with canagliflozin
100 and 300 mg that was generally slightly
higher versus placebo and active comparators.
The incidence of severe hypoglycemia episodes
was low across groups in patients who were not
on background sulfonylurea or insulin (Tables 2
and 3).
Of note, in the study of canagliflozin versus
glimepiride, the incidence of documented
hypoglycemia episodes at week 52 was
significantly lower for canagliflozin 100 and
300 mg versus glimepiride (5.6%, 4.9%, and
34.2%, respectively; p\0.0001) [25]. The
frequency of severe hypoglycemia was also
lower with canagliflozin 100 mg (two patients
[0.4%]) and 300 mg (three patients [0.6%]) than
with glimepiride (15 patients [3.1%]). At
week 104, the proportion of patients with
documented hypoglycemia episodes remained
lower with canagliflozin 100 and 300 mg than
with glimepiride (6.8%, 8.2%, and 40.9%,
respectively) [26]. No additional severe
hypoglycemia events with canagliflozin were
reported after week 52.
As add-on to metformin versus placebo/
sitagliptin, the incidence of documented
hypoglycemia episodes at week 52 was higher
with both canagliflozin doses compared with
sitagliptin 100 mg and with placebo/sitagliptin
[24]. The reason for the higher incidence of
documented episodes of hypoglycemia with
canagliflozin versus sitagliptin and placebo/
sitagliptin in this study is unknown, although
the greater HbA1c lowering seen with
canagliflozin may have contributed to this
difference. However, as add-on to metformin
plus sulfonylurea, the incidence of
hypoglycemia with canagliflozin 300 mg was
similar to sitagliptin (43.2% and 40.7%,
respectively), despite a nearly 0.4% larger
reduction in HbA1c with canagliflozin [30].
Fasting Plasma Lipids and Laboratory
Parameters
Across studies, canagliflozin was generally
associated with reductions in triglycerides and
increases in high-density lipoprotein
cholesterol and low-density lipoprotein
cholesterol [24–32]. In addition, no clinically
meaningful changes in most laboratory
parameters, including alanine
aminotransferase, aspartate aminotransferase,
bilirubin, blood urea nitrogen, creatinine,
urate, and hemoglobin, were seen with
canagliflozin across studies [24–32].
Treatment with canagliflozin in combination
with metformin was associated with a transient
reduction in estimated glomerular filtration
rate (eGFR) that attenuated over time [24–32].
In the 104-week study as add-on to metformin
versus glimepiride [26], canagliflozin was
associated with a slower rate in decline in
eGFR compared with glimepiride, suggesting a
potential renoprotective effect for canagliflozin
[37]. In addition, canagliflozin provided
reductions in albumin-to-creatinine ratio
(ACR) in the studies where ACR was assessed
[25, 26, 37–40]. The ongoing Canagliflozin and
Renal Events in Diabetes With Established
Nephropathy Clinical Evaluation
(CREDENCE; NCT02065791) study will
provide further insight into the renal effects
of canagliflozin in patients with T2DM and
renal impairment.
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CONCLUSION
Improving glycemic control is the cornerstone of
diabetesmanagement, as improvements in blood
glucose levels can decrease the risk of
diabetes-related complications. SGLT2 inhibitors
may be suitable alternative therapeutic agents for
combination therapywithmetformindue to their
favorable glycemic efficacy and added benefits of
weight loss and BP reduction. Treatment with
canagliflozin incombinationwithmetforminwas
associated with reductions in HbA1c, body
weight, and systolic BP versus placebo and active
comparators across Phase 3 studies of up to
104 weeks in duration. Canagliflozin was
generally well tolerated, with an increased
incidence of AEs related to the mechanism of
SGLT2 inhibition and low rates of hypoglycemia.
As genitalmycotic infectionsweremore common
inmale and female patientswith a prior history of
infections and inuncircumcisedmales, awareness
of these potential AEs with canagliflozin is
important for these patient populations. Patients
susceptible to the volume depletion effects of
canagliflozin (i.e., older patients, patients with
moderate renal impairment, and those taking
loop diuretics) should be monitored while on
canagliflozin treatment. The favorable efficacy
and safety profile suggest that adding
canagliflozin to a background treatment
regimen consisting of metformin alone or in
combination with other AHAs, or implementing
treatment with a fixed-dose combination of
canagliflozin and metformin would provide an
effective and safe alternative treatment regimen
for T2DMmanagement.
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